REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Five-membered Hetero Ring Containing At Least One Nitrogen Ring Atom (e.g., 1,2,3-triazoles, Etc.) > Tetrazoles (including Hydrogenated) Tetrazoles (including Hydrogenated)Tetrazoles (including Hydrogenated) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.12/21/06 - 20060287377 - New benzimidazole derivatives wherein R1, m, R2, R3, p, n, R5 and R9 are as defined as in the specification, salts, solvates or solvated salts thereof, processes for their preparation, intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and the use of said compounds in therapy. ... 12/14/06 - 20060281801 - Process for the preparation of valsartan and its intermediates The present invention relates to an improved process for the preparation of valsartan and its intermediates in substantially pure enantiomeric form. In particular, the present invention provides a process for preparing benzyl valsartan intermediate substantially free of organotin impurities. The valsartan produced from such benzyl valsartan intermediate requires significantly lower ... 12/14/06 - 20060281800 - Polymorphic form of olmesartan and process for its preparation A process for the preparation of a novel crystalline polymorph of olmesartan medoxomil, designated Form G, is provided comprising the steps of (a) preparing a solution comprising olmesartan medoxomil and one or more solvents selected from the group consisting of a nitrile, alcohol and mixtures thereof at a suitable temperature ... 12/07/06 - 20060276523 - Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases having wider pharmacological activity and enhanced tolerability. They can be employed for treating cardiovascular, renal and chronic liver diseases and inflammatory processes. ... 11/30/06 - 20060270723 - Process for preparing amorphous valsartan The present invention provides a process for the preparation of amorphous valsartan. ... 11/23/06 - 20060264488 - Tubular proteinuria as an indicator for elevated cardiovascular risk The invention relates to the use of an ACE inhibitor or an angiotensin receptor antagonist for the preparation of a pharmaceutical composition for reducing tubular proteinuria oral/or α1-microglubulin in a non-diabetic human individual for reducing the risk of a cardiovascular event. ... 11/16/06 - 20060258727 - Olmesartan medoxomil with reduced levels of impurities The present invention provides the preparation of olmesartan medoxomil containing less than about 0.1% of one or more of the impurities OLM-Me, OLM-Cl, and OLM-eliminate. ... 11/16/06 - 20060258726 - 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors of formula (I), their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of the patient. This invention further relates to ... 10/26/06 - 20060241161 - Process for preparing losartan potassium with improved flowability Provided is a method of improving the flowability of losartan potassium powder having an initial Hausner ratio of 1.45 or more, which method includes reslurrying the losatrtan potassium in a reslurry solvent. ... 10/12/06 - 20060229350 - Losartan potassium crystalline form alpha Losartan potassium crystalline Form α, a process for its preparation, a pharmaceutical composition therefrom, its use in therapy and in a purification process of losartan potassium. ... 09/28/06 - 20060217429 - Use of inhibitors of the renin-angiotensin system It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and ... 09/14/06 - 20060205801 - Crystal and process for producing the same A process for producing crystals of 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimdazole-7-carboxylic acid (compound (I)), characterized by dissolving or suspending the compound (I) or a salt thereof in a solvent comprising an aprotic polar solvent and crystallizing it. By the process, the contaminants which are contained in the compound (I) or its salt and are ... 09/14/06 - 20060205800 - Therapeutic compounds A compound having a substituted five or six-membered carbocycle or heterocycle directly bonded to a substituted aryl or heteroaryl ring, wherein said compound has an EC50 value of 20 nM or less at the prostaglandin EP2 receptor according to the cAMP assay. Methods, compositions, and medicaments related thereto are also ... 09/07/06 - 20060199853 - Analogs of 4-hydroxyisoleucine and uses thereof The invention relates to analogs of 4-hydroxyisoleucine, and to lactones, pharmaceutically acceptable salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. The analogs of the invention stimulate both glucose uptake and insulin secretion, and may thus be useful for the prevention and treatment ... 08/31/06 - 20060194858 - Preparation of crude candesartan cilexetil A process for preparing candesartan cilexetil comprising heating a solution of trityl candesartan cilexetil in a water immiscible solvent in the presence of at least one C1-C4 alcohol and a first portion of water; combining the solution with a second portion of water to obtain a two-phase system; and recovering ... 08/31/06 - 20060194857 - Novel heteroaryl derivative (wherein Ring Z is an optionally substituted heteroaryl, R1 is a carboxyl group or an alkoxycarbonyl group, etc., W1 and W2 are an optionally substituted lower alkylene, Ar1 is an optionally substituted arylene or an optionally substituted heteroarylene, W3 is a single bond, a lower alkylene, a lower alkenylene, etc., ... 08/31/06 - 20060194856 - Use of atii antagonist for the treatment or prevention of metabolic syndrome The present invention relates to the use of an angiotensin II type 1 receptor antagonist alone, or in combination with a metabolically neutral antihypertensive substance, for the prevention and/or treatment of the metabolic syndrome. ... 08/24/06 - 20060189669 - Pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy and preproliferative retinopathy To provide a pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy or preproliferative retinopathy, comprising a compound having angiotensin II antagonistic activity, or a salt thereof. ... 08/10/06 - 20060178414 - Substituted biaryl amides as c5a receptor modulators Substituted biaryl amides of Formula I are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological C5a receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical ... 08/10/06 - 20060178413 - Diphenylurea derivatives and their use as chloride channel blockers The present invention relates to novel diphenylurea derivatives useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, and to pharmaceutical compositions comprising the compounds of the invention. ... 08/03/06 - 20060173059 - Agent for preventing or treating portal hypertension wherein R1 represents a group capable of forming an anion, etc.; X represents a bond or a spacer; n is an integer of 1 or 2; ring A is benzene ring which may be further substituted; R2 represents a group capable of forming an anion, etc.; and R3 represents a ... 08/03/06 - 20060173058 - Kcnq channel modulating compounds and their pharmaceutical use This invention relates to novel compounds useful as modulators of the KCNQ channel, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith. ... 07/20/06 - 20060160871 - Stable non-crystalline formulation comprising losartan One or more embodiments of the invention provide various novel formulations, and tablet dosage forms, comprising losartan that are non-crystalline, stable, and/or otherwise improvements over known losartan formulations. One or more embodiments of the invention further provide methods for preparing the formulation, methods for preparing the tablet dosage form, and ... 07/13/06 - 20060154976 - Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors A method of treatment of indications which can be positively influenced by inhibition of AT1 mediated effects with maintenance of AT2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, ... 07/06/06 - 20060148871 - Metabolic stabilization of substituted adamantane The present invention is directed to the method of increasing the metabolic stability of adamantane containing compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 (11-beta-HSD-1) enzyme. The stability is achieved by substitutions of the adamantane ring. ... 07/06/06 - 20060148870 - Process for preparing olmesartan medoxomil at ph higher than 2.5 The present invention provides a process for preparing olmesartan medoxomil at pH higher than 2.5. ... 05/25/06 - 20060111411 - Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents The present invention provides compounds of formula I wherein X, Y, R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided. ... 05/18/06 - 20060106079 - Method for preparing oltipraz Provided is a method for preparing oltipraz. The method includes reacting methyl 2-methyl-3-(pyrazin-2-yl)-3oxopropionate with phosphorus pentasulfide in the presence of a mixed solvent of toluene and xylene, followed by recrystallization. ... 05/04/06 - 20060094769 - Novel aminodicarboxylic acid derivatives having pharmaceutical properties wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed. ... 05/04/06 - 20060094768 - Thiophene derivative ppar modulators The present invention is directed to compounds represented by the following structural formula, Formula I: and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) X is selected from the group consisting of O, S, S(O)2, N, and a bond; (b) U is an aliphatic linker wherein one carbon ... 04/06/06 - 20060074117 - Purification of olmesartan medoxomil The present invention provides a process for purifying olmesartan medoxomil. ... 03/30/06 - 20060069141 - Preparation of olmesartan medoxomil The present invention provides a process for preparing olmesartan medoxomil. ... 03/30/06 - 20060069140 - Pyrazolone compounds and thrombopoietin receptor activator A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): wherein A is a C?2-14#191 aryl group, B is a hydrogen atom, a C?1-6#191 alkyl group, a ... 03/09/06 - 20060052427 - N-phenylbenzamide derivatives as drugs for the treatment of copd wherein R1 is cyano, nitro, halogen, hydroxy, C1-C4 alkyl, methoxy or tetrazol-5-yl group, R2 is hydrogen, hydroxy or methoxy, R3 is a tetrazol-5-yl group or hydrogen, R4 and R5 are hydrogen if R3 is tetrazol-5-yl group, or R4 and R5 are independently selected from the group consisting of carboxy, methoxycarbonyl, ... 02/16/06 - 20060035949 - Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are ... 02/16/06 - 20060035948 - Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them The present invention relates to benzopyran derivatives substituted with secondary amines including tetrazole, method for preparing thereof and pharmaceutical compositions containing them. The compounds of the present invention can be used for protecting neuronal cells and brain damage; antioxidation; inhibiting NO generation; protecting heart; suppressing angiogenesis; protecting preserving organs such ... 01/26/06 - 20060020005 - Process for preparing losartan A process for preparing losartan, comprising reacting trityl losartan with an aqueous acid. ... 01/12/06 - 20060009502 - Medicine for prevention of and treatment for arteriosclerosis and hypertension and (B) a calcium channel blocker selected from the group consisting of a 1,4-dihydropyridine compound and a pharmacologically acceptable salt thereof (for example, azelnidipine), for the prophylaxis and/or treatment of arteriosclerosis, hypertension, heart diseases, renal diseases or cerebrovascular diseases. ... 12/29/05 - 20050288346 - Acetophenone potentiators of metabotropic glutamate receptors The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed ... 12/29/05 - 20050288345 - Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections. ... 12/29/05 - 20050288344 - Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection. ... 12/22/05 - 20050282877 - Method of decreasing inflammation in kidney transplantion using angiotensin receptor blockers Disclosed is a method of inhibiting production of IFN-Γ in patients having a transplanted organ. The method involves administering to the patient an amount of an angiotensin receptor-blocking compound, the amount being effective to inhibit production of IFN-Γ by T cells. The method can be used to treat inflammation involving ... 12/08/05 - 20050272789 - Triazole-derived kinase inhibitors and uses thereof where Ht, R2, T, and m are as described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. ... 12/08/05 - 20050272788 - Indoles having anti-diabetic activity Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 ... 12/01/05 - 20050267183 - Selective estrogen receptor modulators The present invention provides, inter alia, triphenylethylene derivatives, such as, 5-{2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-1H-tetrazole, as selective estrogen receptor modulators. Also provided are methods for treating estrogen stimulated diseases in mammals including, but not limited to, for example, breast, uterine, ovarian, prostate and colon cancer; osteoporosis; endometriosis; uterine fibroid; Alzheimer's disease; macular degeneration; urinary ... 11/10/05 - 20050250828 - Candesartan cilexetil polymorphs Provided are candesartan cilexetil forms and methods of their preparation. Also provided are pharmaceutical compositions prepared by combining at least one pharmaceutically-acceptable excipient with at least one candesartan cilexetil form of the invention. ... 11/10/05 - 20050250827 - Preparation of candesartan cilexetil in high purity The present invention is directed to the preparation of substantially pure candesartan cilexetil by the deprotection of trityl candesartan cilexetil and crystallization and/or recrystallization of candesartan cilexetil. ... 10/06/05 - 20050222233 - Polymorphs of valsartan Provided are crystalline and amorphous form of valsartan, and processes for their preparation. ... 10/06/05 - 20050222232 - Compositions and methods for treating hair loss using non-naturally occurring prostaglandins A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. ... 10/06/05 - 20050222231 - Prodrugs of excitatory amino acids This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders. ... 10/06/05 - 20050222230 - 3,4-diarylpyrazoles and their use in the therapy of cancer The present invention pertains to the use of certain 3,4-diarylpyrazoles of formula (I), both in vitro and in vivo, to inhibit heat shock protein 90 (HSP90), and in the treatment of conditions mediated by HSP90, including, for example, cancer; wherein: Ar3 is independently: a C5-20aryl group, and is optionally substituted; ... 09/22/05 - 20050209293 - Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-ht, receptor antagonist A method of treating or inhibiting non-digestive tract derived abdominal disorders associated with pain, in particular interstitial cystitis, chronic pelvic pain syndrome and/or abdominal pain associated with endometriosis, in a patient in need thereof, by administering to the patient a pharmaceutically effective amount of a 5-HT3 receptor antagonist, in particular ... 09/08/05 - 20050197373 - Substituted fused bicyclic amines as modulators of chemokine receptor activity or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5′, R6, a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and ... 09/08/05 - 20050197372 - Use of valsartan or its metabolite to inhibit platelet aggregation The invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of an ARB or its metabolite, especially Valsartan or its metabolite valeryl 4-hydroxy valsartan. Conditions to be treated by inhibition of platelet aggregation include acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, ... 09/01/05 - 20050192327 - Use of inhibitors of the renin-angiotensin system It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and ... 09/01/05 - 20050192326 - Use of inhibitors of the renin-angiotensin system It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and ... 08/18/05 - 20050182115 - Agent for preventing and/or treating sinusitis or a salt and/or hydrate thereof. The pranlukast hydrate is useful as an agent for preventing and/or treating sinusitis. ... 08/18/05 - 20050182114 - Novel crystalline forms of candesartan cilexetil The present invention relates to two novel crystalline forms and a novel 1,4-dioxane solvate of candesartan cilexetil, to processes for their preparation and to pharmaceutical compositions containing them. ... 08/11/05 - 20050176794 - Novel synthesis of irbesartan Provided is a novel synthesis of irbesartan employing a phase transfer catalyst. Also provided is irbesartan having a fine particle size. ... 08/11/05 - 20050176793 - Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one The present invention relates to a novel amorphous form of 2-n-butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one and to a process for preparation thereof. Irbesartan (2-n-Butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4] non-1-en-4-one), represented by the following formula (I), is a non-peptide angiotensin—II antagonist. By inhibiting the action of angiotensin—II on its receptors, this compound prevents the increase in blood pressure produced ... 07/28/05 - 20050165075 - Novel amorphous form of valsartan The present invention relates to a novel amorphous form of valsartan, to a process for its preparation and to a pharmaceutical composition containing it. ... 07/21/05 - 20050159467 - 5-aryltetrazole compounds and uses thereof The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound. ... 06/30/05 - 20050143436 - Inhibitors of interleukin-1beta converting enzyme The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly ... 06/30/05 - 20050143435 - Pharmaceutical compositions comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker Parmaceutical compositions comprising selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions comprising Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes. ... 06/16/05 - 20050131040 - Process for the preparation of crystalline losartan potassium A process for the preparation of crystalline losartan potassium and crystalline hydrate losartan potassium. ... 06/16/05 - 20050131039 - Benzimidazole derivatives, their production and use wherein R is triphenylmethyl, 2-tetrahydropyranyl, methoxymethyl or ethoxy methyl, the other symbols as defined above; or a salt thereof. ... 06/16/05 - 20050131038 - Process for the preparation of valsartan and intermediates thereof A novel process for the preparation of valsartan and novel intermediates useful in the preparation thereof. ... 06/16/05 - 20050131037 - Preparation of candesartan cilexetil The invention encompasses processes for the synthesis of cilexetil trityl candesartan from the reaction of trityl candesartan with cilexetil halide in the presence of a base and a low boiling organic solvent. Optionally, the reaction may be conducted in the presence of a phase transfer catalyst. ... 06/09/05 - 20050124676 - Ep4 receptor antagonists wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl. ... 06/02/05 - 20050119323 - Anticancer agents Remedies/preventives for hormone-independent cancer, hormone-independent cancer cell proliferation inhibitors, apoptosis inducers for cancer cells, etc. each containing a compound having an angiotensin II antagonism, its prodrug or a salt thereof. Thus, excellent anticancer agents are provided. ... ### FreshPatents.com Support |